Verrica Pharmaceuticals Financials

VRCA

Key Financial Metrics

Revenue

$7.6M

YoY+47.7%

Verrica Pharmaceuticals generated $7.6M in revenue in fiscal year 2024. This represents an increase of 47.7% from the prior year.

EBITDA

-$65.0M

YoY+0.4%

Verrica Pharmaceuticals's EBITDA was -$65.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 0.4% from the prior year.

Free Cash Flow

-$61.0M

YoY-56.5%

Verrica Pharmaceuticals generated -$61.0M in free cash flow in fiscal year 2024, representing cash available after capital expenditures. This represents a decrease of 56.5% from the prior year.

Net Income

-$76.6M

YoY-14.3%

Verrica Pharmaceuticals reported -$76.6M in net income in fiscal year 2024. This represents a decrease of 14.3% from the prior year.

EPS (Diluted)

$-1.48

YoY+0.0%

Verrica Pharmaceuticals earned $-1.48 per diluted share in fiscal year 2024. This represents an increase of 0.0% from the prior year.

Cash & Debt

$46.3M

YoY-33.4%

5Y CAGR+38.0%

Verrica Pharmaceuticals held $46.3M in cash against $31.0M in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

YoY-78.4%

5Y CAGR-18.7%

Verrica Pharmaceuticals had 9M shares outstanding in fiscal year 2024. This represents a decrease of 78.4% from the prior year.

Gross Margin

65.6%

YoY-24.6pp

Verrica Pharmaceuticals's gross margin was 65.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 24.6 percentage points from the prior year.

Operating Margin

-871.3%

YoY+412.1pp

Verrica Pharmaceuticals's operating margin was -871.3% in fiscal year 2024, reflecting core business profitability. This is up 412.1 percentage points from the prior year.

Net Margin

-1012.1%

YoY+295.3pp

Verrica Pharmaceuticals's net profit margin was -1012.1% in fiscal year 2024, showing the share of revenue converted to profit. This is up 295.3 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$11.8M

YoY-41.7%

5Y CAGR-5.2%

Verrica Pharmaceuticals invested $11.8M in research and development in fiscal year 2024. This represents a decrease of 41.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$27K

YoY-92.5%

5Y CAGR-47.6%

Verrica Pharmaceuticals invested $27K in capital expenditures in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 92.5% from the prior year.

VRCA Income Statement

Metric	FY24	FY24	FY23	FY22	FY21	FY20
Revenue	$7.6M+47.7%	$5.1M-43.3%	$9.0M-24.7%	$12.0M	N/A	N/A
Cost of Revenue	$2.6M+420.0%	$500K	N/A	N/A	N/A	N/A
Gross Profit	$5.0M+7.4%	$4.6M	N/A	N/A	N/A	N/A
R&D Expenses	$11.8M-41.7%	$20.3M+66.4%	$12.2M-23.4%	$15.9M+1.6%	$15.7M+1.5%	$15.4M
SG&A Expenses	$58.8M+24.3%	$47.3M+171.8%	$17.4M-35.5%	$27.0M+10.1%	$24.5M+67.4%	$14.6M
Operating Income	-$65.9M-0.2%	-$65.8M-208.8%	-$21.3M+31.1%	-$30.9M+23.1%	-$40.2M-33.6%	-$30.1M
Interest Expense	$9.4M+137.6%	$4.0M+82.4%	$2.2M-49.4%	$4.3M+41.6%	$3.0M	N/A
Income Tax	$0	$0	$0	N/A	N/A	N/A
Net Income	-$76.6M-14.3%	-$67.0M-173.6%	-$24.5M+30.2%	-$35.1M+17.8%	-$42.7M-51.4%	-$28.2M
EPS (Diluted)	$-1.480.0%	$-1.48-105.6%	$-0.72+44.6%	$-1.30	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$14.3M+12.9%	$12.7M+269.4%	$3.4M	N/A	-$1.8M-134.4%	$5.2M+35.3%	$3.8M	N/A
Cost of Revenue	N/A	N/A	$700K	N/A	$400K-42.9%	$700K0.0%	$700K	N/A
Gross Profit	N/A	N/A	$2.7M	N/A	-$2.2M-148.7%	$4.5M+43.2%	$3.1M	N/A
R&D Expenses	$2.2M+19.4%	$1.8M-19.2%	$2.3M	N/A	$2.4M-27.5%	$3.3M-32.9%	$4.9M	N/A
SG&A Expenses	$9.4M+6.2%	$8.9M0.0%	$8.8M	N/A	$16.1M-2.7%	$16.5M+1.1%	$16.3M	N/A
Operating Income	$1.6M+7.7%	$1.5M+118.6%	-$8.1M	N/A	-$20.7M-36.2%	-$15.2M+18.2%	-$18.6M	N/A
Interest Expense	$2.1M-1.7%	$2.1M-3.3%	$2.2M	N/A	$2.4M+0.3%	$2.4M+2.1%	$2.3M	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$274K-234.3%	$204K+102.1%	-$9.7M	N/A	-$22.9M-33.0%	-$17.2M+15.5%	-$20.3M	N/A
EPS (Diluted)	$-0.03-250.0%	$0.02+120.0%	$-0.10	N/A	$-4.88-31.9%	$-3.70-740.9%	$-0.44	N/A

VRCA Balance Sheet

Metric	FY24	FY24	FY23	FY22	FY21	FY20
Total Assets	$54.1M-33.7%	$81.6M+82.5%	$44.7M-44.2%	$80.1M+8.1%	$74.2M+8.4%	$68.4M
Current Assets	$51.2M-34.0%	$77.5M+98.2%	$39.1M-47.4%	$74.3M+9.9%	$67.7M+4.1%	$65.0M
Cash & Equivalents	$46.3M-33.4%	$69.5M+102.9%	$34.3M+117.6%	$15.8M+47.4%	$10.7M+15.6%	$9.2M
Inventory	$2.5M+141.0%	$1.0M	$0	N/A	N/A	N/A
Accounts Receivable	$48K-98.9%	$4.2M	$0	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$64.0M+3.5%	$61.8M+1219.0%	$4.7M-90.1%	$47.5M+15.4%	$41.2M+1107.6%	$3.4M
Current Liabilities	$29.0M+70.4%	$17.0M+392.2%	$3.5M-92.5%	$46.1M+16.7%	$39.5M+1078.0%	$3.4M
Long-Term Debt	$31.0M-27.7%	$42.9M	$0	N/A	N/A	N/A
Total Equity	-$9.9M-149.9%	$19.8M-50.6%	$40.0M+22.8%	$32.6M-1.2%	$33.0M-49.3%	$65.0M
Retained Earnings	-$307.0M-33.2%	-$230.4M-41.0%	-$163.5M-17.6%	-$139.0M-33.8%	-$103.9M-69.8%	-$61.2M

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$40.9M+4.6%	$39.1M-7.3%	$42.2M-22.1%	$54.1M+64.4%	$32.9M-36.7%	$52.0M-21.6%	$66.3M-18.7%	$81.6M
Current Assets	$36.3M-1.4%	$36.8M-6.8%	$39.5M-22.9%	$51.2M+81.6%	$28.2M-40.4%	$47.3M-22.9%	$61.4M-20.8%	$77.5M
Cash & Equivalents	$21.1M+37.0%	$15.4M-48.0%	$29.6M-36.1%	$46.3M+101.8%	$23.0M-28.1%	$31.9M-34.8%	$48.9M-29.6%	$69.5M
Inventory	$2.3M-8.6%	$2.5M+2.6%	$2.5M-0.2%	$2.5M-4.7%	$2.6M-4.4%	$2.7M+8.2%	$2.5M+144.5%	$1.0M
Accounts Receivable	$7.0M-23.3%	$9.2M+64.0%	$5.6M+11581.3%	$48K	$0-100.0%	$10.0M+43.2%	$7.0M+64.8%	$4.2M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$57.9M+2.4%	$56.6M-6.9%	$60.8M-5.1%	$64.0M-4.5%	$67.0M+2.6%	$65.3M+0.8%	$64.8M+4.8%	$61.8M
Current Liabilities	$28.9M-1.1%	$29.2M-0.6%	$29.4M+1.3%	$29.0M+38.0%	$21.0M+4.9%	$20.1M+3.5%	$19.4M+13.8%	$17.0M
Long-Term Debt	$21.6M-12.0%	$24.6M-11.6%	$27.8M-10.2%	$31.0M-28.5%	$43.3M+1.3%	$42.8M-0.2%	$42.8M-0.1%	$42.9M
Total Equity	-$17.0M+2.5%	-$17.5M+5.9%	-$18.6M-88.4%	-$9.9M+71.0%	-$34.1M-156.0%	-$13.3M-982.0%	$1.5M-92.4%	$19.8M
Retained Earnings	-$316.8M-0.1%	-$316.6M+0.1%	-$316.8M-3.2%	-$307.0M-5.6%	-$290.8M-8.5%	-$268.0M-6.9%	-$250.8M-8.8%	-$230.4M

VRCA Cash Flow Statement

Metric	FY24	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$60.9M-57.9%	-$38.6M-106.8%	-$18.6M+32.4%	-$27.6M+8.7%	-$30.2M-10.2%	-$27.4M
Capital Expenditures	$27K-92.5%	$362K+19.9%	$302K-65.8%	$883K-39.9%	$1.5M+115.5%	$682K
Free Cash Flow	-$61.0M-56.5%	-$38.9M-105.5%	-$19.0M+33.4%	-$28.5M+10.1%	-$31.7M-12.8%	-$28.1M
Investing Cash Flow	-$19K+94.8%	-$362K-100.7%	$54.0M+5514.9%	-$998K+72.1%	-$3.6M-113.8%	$26.0M
Financing Cash Flow	$37.7M-49.2%	$74.2M+539.9%	-$16.9M-150.1%	$33.6M-4.5%	$35.2M+8229.1%	$423K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	N/A	N/A	-$12.7M	N/A	N/A	N/A	-$19.9M	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$19.9M	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Financing Cash Flow	N/A	N/A	-$4.1M	N/A	N/A	N/A	-$661K	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

VRCA Financial Ratios

Metric	FY24	FY24	FY23	FY22	FY21	FY20
Gross Margin	65.6%-24.6pp	90.2%	N/A	N/A	N/A	N/A
Operating Margin	-871.3%+412.1pp	-1283.4%-1047.6pp	-235.8%+21.8pp	-257.6%	N/A	N/A
Net Margin	-1012.1%+295.3pp	-1307.5%-1036.4pp	-271.1%+21.2pp	-292.3%	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-141.5%-59.4pp	-82.1%-27.3pp	-54.8%-11.0pp	-43.8%+13.8pp	-57.6%-16.3pp	-41.2%
Current Ratio	1.76-2.8	4.55-6.8	11.31+9.7	1.61-0.1	1.71-17.7	19.39
Debt-to-Equity	-3.14-5.3	2.17+2.2	0.00-1.5	1.46+0.2	1.25+1.2	0.05
FCF Margin	-805.6%-45.7pp	-759.9%-550.1pp	-209.8%+27.4pp	-237.2%	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	N/A	N/A	79.7%	N/A	N/A	86.5%+4.8pp	81.7%	N/A
Operating Margin	11.3%-0.6pp	11.9%+248.3pp	-236.4%	N/A	N/A	-293.7%+192.4pp	-486.1%	N/A
Net Margin	-1.9%-3.5pp	1.6%+284.9pp	-283.3%	N/A	N/A	-332.0%+199.4pp	-531.4%	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-0.7%-1.2pp	0.5%+23.6pp	-23.1%	N/A	-69.4%-36.4pp	-33.0%-2.4pp	-30.7%	N/A
Current Ratio	1.250.0	1.26-0.1	1.34-0.4	1.76+0.4	1.34-1.0	2.36-0.8	3.17-1.4	4.55
Debt-to-Equity	-1.27+0.1	-1.41+0.1	-1.50+1.6	-3.14-1.9	-1.27+1.9	-3.21-31.6	28.41+26.2	2.17
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-521.4%	N/A

Frequently Asked Questions

What is Verrica Pharmaceuticals's annual revenue?

Verrica Pharmaceuticals (VRCA) reported $7.6M in revenue for fiscal year 2024.

How fast is Verrica Pharmaceuticals's revenue growing?

Verrica Pharmaceuticals (VRCA) revenue grew by 47.7% year-over-year, from $5.1M to $7.6M in fiscal year 2024.

Is Verrica Pharmaceuticals profitable?

No, Verrica Pharmaceuticals (VRCA) reported a net income of -$76.6M in fiscal year 2024, with a net profit margin of -1012.1%.

What is Verrica Pharmaceuticals's earnings per share (EPS)?

Verrica Pharmaceuticals (VRCA) reported diluted earnings per share of $-1.48 for fiscal year 2024.

What is Verrica Pharmaceuticals's EBITDA?

Verrica Pharmaceuticals (VRCA) had EBITDA of -$65.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Verrica Pharmaceuticals have?

As of fiscal year 2024, Verrica Pharmaceuticals (VRCA) had $46.3M in cash and equivalents against $31.0M in long-term debt.

What is Verrica Pharmaceuticals's gross margin?

Verrica Pharmaceuticals (VRCA) had a gross margin of 65.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Verrica Pharmaceuticals's operating margin?

Verrica Pharmaceuticals (VRCA) had an operating margin of -871.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Verrica Pharmaceuticals's net profit margin?

Verrica Pharmaceuticals (VRCA) had a net profit margin of -1012.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Verrica Pharmaceuticals's free cash flow?

Verrica Pharmaceuticals (VRCA) generated -$61.0M in free cash flow during fiscal year 2024, representing cash available after capital expenditures.

What is Verrica Pharmaceuticals's operating cash flow?

Verrica Pharmaceuticals (VRCA) generated -$60.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Verrica Pharmaceuticals's total assets?

Verrica Pharmaceuticals (VRCA) had $54.1M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Verrica Pharmaceuticals's capital expenditures?

Verrica Pharmaceuticals (VRCA) invested $27K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Verrica Pharmaceuticals spend on research and development?

Verrica Pharmaceuticals (VRCA) invested $11.8M in research and development during fiscal year 2024.

How many shares does Verrica Pharmaceuticals have outstanding?

Verrica Pharmaceuticals (VRCA) had 9M shares outstanding as of fiscal year 2024.

What is Verrica Pharmaceuticals's current ratio?

Verrica Pharmaceuticals (VRCA) had a current ratio of 1.76 as of fiscal year 2024, which is generally considered healthy.

What is Verrica Pharmaceuticals's debt-to-equity ratio?

Verrica Pharmaceuticals (VRCA) had a debt-to-equity ratio of -3.14 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Verrica Pharmaceuticals's return on assets (ROA)?

Verrica Pharmaceuticals (VRCA) had a return on assets of -141.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.